Global Research Antibodies and Reagents Market

The cell based assays market consists of sales of cell based assays. Cell-based assays are analytical tools that are designed to study a mechanism or process of cellular function. Companies developing cell based assays provide consumables such as reagents, assays kits and microplates as well as instruments, services and software. This report includes sales of reagents, cell lines, microplates, microplate, assay kits, probes and labels, and others. The main product and services of cell based assays are consumables, instruments, services, and software. Consumables are products that are used up or depleted throughout their use. The various instruments used are microplates, microplate readers, high throughput screening, and liquid handling systems and different consumables include reagents and media, cells and cell lines, probes and labels. The several technology types of cell based assays are automated handling, flow cytometry, label-free detection, high-throughput screening, others and are applied for drug discovery, basic research, ADME studies, predictive toxicology, others. The different end users include pharmaceutical and biotechnology companies, academic and government research institutes, Contract Research Organizations (CRO) and others The global cell based assays market size is expected to grow from $20.73 billion in 2021 to $22.58 billion in 2022 at a compound annual growth rate (CAGR) of 9%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cell based assays market is expected to reach $31.87 billion in 2026 at a CAGR of 9%. Research with cell based arrays is increasing with evolution and there is a definite need to move to more predictive cellular models for drug discovery in order to control the last-stage drug failures. The pharmaceutical industries’ need to efficiently commercialize drugs in order to overcome expensive failures in the last stages is a driving force in cell-based assay innovation. Failure of Investigational New Drug (IND) Phase III clinical trials results in a loss of several hundred million dollars to that company. For instance, according to report by Sigma, the return on investment for pharmaceutical companies could drop to 5% considering the current level of late-stage failures, and is an unacceptable level for most companies. Major improvements to high-content systems and data analysis from the cell based assays enable scientists to extract a more information about the cellular response and help take informed decisions during drug discovery, and further driving the market for cell based arrays. High cost of instruments is the major factor restraining the global cell based assays market. High price of the instrumentation will reduce the return on investments (ROI) owing to low adaptation. For example, Biotek developed HCA (High Content Analysis) instruments and are expensive and reserved for industrial end-users or core labs which have sufficient capital budgets. This restricts the low budgeted end-users to use cell based assays to its full potential, thereby hampering the growth of the market. Researchers are inclining towards early phase predictive toxicity testing that prevent late-stage drug failures. Predictive cell toxicity assays are being scaled up to increase screening of compounds in the early phases of drug development, reducing the cost of failure. For instance, Creative Bioarray, a biotech company provides a range of in vitro toxicity services to check drug-induced toxicities that save time and cost by reducing the chance of failure in earlier stage. These advances will make clinical testing easy and reduce the cost of operation. In April 2019, PerkinElmer, a global corporation for diagnostics, life science research, food, environmental and industrial testing acquired Cisbio Bioassays for an undisclosed amount. The acquisition expands PerkinElmer's R&D capability in cell based assay, and customer base in key growth geographies including the Americas, Europe, and China in order to expand its market reach for reagents. Cisbio Bioassays is a custom assay service provider based in Codolet, France and was founded in 1974. Major players in the cell based assays market are Thermo Fisher, Danaher, Becton, Dickinson and Company, GE Healthcare, Merck, Perkinelmer, Promega, Lonza, Charles River Laboratories and Cell Signaling Technology. The regions covered in the cell based assays market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cell based assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global cell based assays market is segmented - 1) By Product and Service: Consumables, Instruments, Services, Software  2) By Application: Drug Discovery, Basic Research, Adme Studies, Predictive Toxicology, Others 3) By End User: Pharmaceutical and Biotechnology Companies, Academic and Government Research Institutes, Contract Research Organizations (CRO), Other End Users 4) By Technology: Automated Handling, Flow Cytometry, Label-Free Detection, High-Throughput Screening, Others 5) By Consumables: Reagents and Media, Cells and Cell Lines, Probes and Labels 6) By Instruments: Microplates, Microplate Readers, High Throughput Screening, Liquid Handling Systems

The flow cytometry market consists of sales of flow cytometry instruments, software and chemicals and related services. Flow cytometry is used to analyze characteristics of a biological cell such as cell size, cell count and cell complexity using laser optics. In the flow cytometry technique, cells are added to a fluid medium which is then passed through a pulsating laser beam. The cell then scatters the beam in different directions towards receptors that capture the light and translate it to data displayed on a monitor. The main types of flow cytometry are instruments, reagents and consumables, software, accessories, and services. Flow cytometry services include experimental design, specimen processing, acquisition and data analysis to support researchers, biotech and pharmaceutical companies in the process of drug development. The various technologies involved are cell-based, bead-based that are used in oncology, drug discovery, disease diagnosis, stem cell therapy, organ transplantation, and hematology. The different end-users include hospitals and clinics, academia and research institutes, pharmaceutical and biotechnology companies, and other end users. The global flow cytometry market size is expected to grow from $4.11 billion in 2020 to $4.52 billion in 2021 at a compound annual growth rate (CAGR) of 10%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The flow cytometry market is expected to reach $6.07 billion in 2025 at a CAGR of 7.6%. The increasing number of HIV cases globally is an important driver for the flow cytometry market. This is because the flow cytometry technique has its direct application in HIV diagnosis. Flow cytometry uses light scattering to determine the identity of cells. These cells are given certain markers called CDs (Clusters of Differentiation), based on the type of scattering. For the HIV virus cell, the clusters of differentiation is called CD4, and based on the number of CD4s in a medium, flow cytometry can be used to diagnose HIV. As the global HIV population continues to grow, the demand for diagnosis techniques such as flow cytometry is also increasing. The availability of cheaper and better substitutes for flow cytometry is a major restrain on the flow cytometry market. These substitutes include ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay. While flow cytometry, ELISA and radioimmunoassay are all methods that help in HIV diagnosis by detecting “problem cells” in a group of cells, ELISA and radioimmunoassay are cheaper and easier methods than flow cytometry. In ELISA, colour changes in reagents are used to detect problematic cells. While in radioimmunoassay, cells are given certain radioactive markers which are used to detect problematic cells. Both ELISA and radioimmunoassay can be implemented using cheap, traditional laboratory equipment and reagents with a higher throughput rate. However, flow cytometry involves high setup costs and costs of interpreting data along with a very low throughput. High-throughput flow cytometry is an emerging trend in the flow cytometry market. This is due to high speed of cell parameter processing and capability to analyze several heterogeneous cell groups at once, using this technique. Traditional cytometry methods are very slow, especially when several cells need to be tested within a day. Using high-throughput flow cytometry methods such as Fluorescence-Activated Cell-Sorting (FACS), multiple cells can be allotted fluorescent markers which can be used to analyze their parameters in quick time. Examples of companies that offer high-throughput flow cytometry solutions include AstraZeneca and Novartis. The US FDA's Code of Federal Regulations (CFR) includes regulations related to a flow cytometry device called the Automated Differential Cell Counter (ADCC). An ADCC is a device used in the study of blood cells, mainly for the detection of faulty blood cells and low blood cell counts. This device comes under the purview of the class 2 special controls guidance document which outlines requirements such as the methods for accurate and precise reporting of results, the statistical linearity conditions of graph-based cytometry results and the types of specimens to be used. Flow cytometry device manufacturers must conform to these guidelines, which address the specific health risks associated with ADCC devices. Hence, this is expected to maintain a vigil on flow cytometry companies involved in manufacturing ADCC. In February 2019, Danaher acquired the biopharma business of GE Life Sciences for $21.4 billion. This acquisition will help Danaher to improve its existing bioprocessing capabilities. The biopharma division of GE Life Sciences is involved in the development and production of biologic drugs, vaccines and cell therapies. It develops products and solutions that facilitate research into fundamental cell and protein biology. GE Life Sciences is a division of GE Healthcare, which was founded in 1994 and has its headquarters in Illinois, the USA. Major players in the flow cytometry market are Beckman Coulter, Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher, Luminex, Miltenyi Biotec, Becton Dickinson and Company, Sysmex, Merck KGAA, Danaher Corporation, Apogee, Stratedigm, General Electric Company, EMD Millipore, Affymetrix, Biomérieux S.A., Cytonome St, Enzo Life Sciences, Enzo Biochem, Sony Biotechnology, Sysmex Partec, Life Technologies, BD, ACEA BIO, and TAKARA BIO The regions covered in the flow cytometry market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the flow cytometry market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global flow cytometry market is segmented - 1) By Type: Instruments, Reagents and Consumables, Software, Accessories, Services 2) By Technology: Cell-Based, Bead-Based 3) By End User: Hospitals and Clinics, Academia and Research Institutes, Pharmaceutical and Biotechnology Companies, Other End Users 4) By Application: Oncology, Drug Discovery, Disease Diagnosis, Stem Cell Therapy, Organ Transplantation, Hematology

The genomics market consists of sales of single-cell genomics and related goods. The study of genomes is called genomics. Single-cell genomics is an innovative method of classifying individual cells from a tissue sample, capable of defining unique traits and identifying rare cell types. Genomics is used in different fields of study such as intragenomic phenomenon including pleiotropy, epistasis, heterosis, and other interactions between loci and alleles within the genome. The main product types of genomics are instrument (including systems, service contract and software), reagents (including reagents and consumables). A reagent is a material or compound that is added to a system to produce a chemical reaction or to determine whether or not a reaction occurred. The different processes include cell isolation, sample preparation, and genomic analysis that are used by academic institutes, biopharmaceutical companies, and clinical research institutes. The global genomics market size is expected to grow from $27.58 billion in 2021 to $32.56 billion in 2022 at a compound annual growth rate (CAGR) of 18.1%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The genomics market is expected to reach $63.50 billion in 2026 at a CAGR of 18.2%. Rising government funds for research on genomics drives the growth of the single-cell genomics market. The government funding focuses on efforts to resolve the complexity of the human genome, define the genomic basis of human health and disease, and ensure that genomics is used safely to enhance patient care and benefit society through government, public and private institutions. For instance, in 2019, the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama, has been selected by the All of Us Research Program to investigate the application of cutting-edge DNA sequencing technologies that could potentially enhance diagnosis and treatment of many common and rare diseases. The National Center for Advancing Translational Sciences (NCATS) has funded $7 million for the research. The technology limitation in single-cell genomics hinders the growth of the single-cell genomics market. Due to cost and technical constraints, the use of genetic sequencing to better target and treat rare and chronic diseases was largely out of reach for most health care organizations. Therefore, limiting the genomics market growth. Companies are investing in new product launches to increase their revenue and expand their consumer base and also for gaining a competitive edge over their rivals. For instance, in June 2021, QIAGEN, a Netherlands-based provider of sample and assay technologies for molecular diagnostics, applied testing, academic, and pharmaceutical research, has announced the release of the QIAprep& CRISPR Kit and CRISPR Q-Primer Solutions, which enable researchers to analyse edited genetic material with unprecedented speed and efficiency to determine how their interventions have changed the function of the DNA sequence in question. In November 2019, Exact Sciences Corp., a USA-based molecular diagnostics company specialized in colon cancer screening, screening test research, and development, non-invasive cancer screening for early detection and prevention of colorectal cancer, acquired Genomic Health Inc. for $2.8 billion in cash. The acquisition is expected to help Exact Sciences Corp. to broaden its offering of cancer tests and expand its footprint in more than 90 countries. Genomic Health Inc. is a USA-based life science company that specializes in the development of genomic-based clinical diagnostic tests for cancer. Major players in the genomics market are 10X Genomics, Qiagen NV, Fluidigm Corporation, Johnson & Johnson Private Limited, Zephyrus Biosciences Inc., Illumina Inc., Affymetrix, Angle PLC, Denovo Sciences Inc., Diagnologix LLC, DNA Electronics Ltd, Enumeral, Epic Sciences, Kellbenx Inc., Resolution Bio Science Inc., Wafergen Bio-systems Inc., Yikon Genomics Co. Ltd, Thermo Fisher Scientific Inc., CellBio, Beckman Coulter, Becton Dickinson, Bio-Rad, Carl Zeiss Microscopy, Cell Microsystems, Cellsee Diagnostics, CellSorter, Cytena, CytoTrack, Dolomite Bio, Agilent Technologies Inc., and Fluxion Biosciences. The regions covered in the genomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the genomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global genomics market is segmented - 1) By Product Type: Instrument (Including Systems, Service Contract and Software), Reagents (Including Reagents and Consumables) 2) By Process: Cell Isolation, Sample Preparation, Genomic Analysis 3) By End User: Academic Institutes, Biopharmaceutical Companies, Clinical Research Institutes

The proteomics market consists of sales of proteomics and related goods. Proteomics is a study of the structure and functions of proteins that are used in drug discovery, diagnosis, and treatment of diseases. Proteomics is used to evaluate the protein production rate, the involvement of proteins in metabolic pathways, and modifications of proteins. The main types of proteomics are protein microarrays, spectroscopy, X-Ray crystallography, chromatography, electrophoresis, surface plasmon resonance, and protein fractionation. The various component used are reagents, instruments and software that are used for proteomic analytical services and instrument services. The global proteomics market size is expected to grow from $23.70 billion in 2021 to $26.98 billion in 2022 at a compound annual growth rate (CAGR) of 13.8%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The proteomics market is expected to reach $44.96 billion in 2026 at a CAGR of 13.6%. Rising government funds for research on proteomics drives the growth of the proteomics market. Government funds help researchers in drug discovery, diagnosis, and treatment of diseases. For instance, in 2020, the IRB Barcelona's Mass Spectrometry and Proteomics Core Facility, which is led by a research team with extensive expertise in the field, has received funding from the Catalan government through the European Regional Development Fund (ERDF) to purchase next-generation protein analysis equipment in collaboration with the Josep Carreras Leukemia Research Institute (IJC), the Sant Joan de Déu Research Institute (SJD), the Vall d'Hebron Institute of Oncology (VHIO), and the (UB). Therefore, rising government funds positively impacts the proteomics market. The high cost of instruments is expected to limit the growth of the proteomics market. The broad implementation of new technologies expands the use of proteomics research from the discovery of new drugs, vaccines and diagnostic targets, and due to its high-cost process, developments in different instruments have resulted in high prices compared to the traditional ones. For instance, the price of mass spectrometers can range from $20,000 to $300,000, which will be extremely expensive for small-scale pharmaceutical companies and academic institutions. Therefore, the high prices associated with proteomics instruments makes it difficult for developing countries to enter the proteomics sector, affecting the proteomics market’s growth. Companies are launching new products in order to increase their revenue and also gain a competitive edge over their rivals. For instance, in June 2021, Bruker Corporation, a USA-based scientific instruments manufacturing company, announced the availability of two new trapped ion mobility spectrometry time-of-flight (timsTOF) instruments at its 4D-Proteomics eXceed Symposium. The devices, which are based on ion mobility separation and mass spectrometry, will provide additional advances in proteomics, epiproteomics/PTM characterisation, and deep multiomic biomarker discovery. In January 2020, Abcam, a UK-based company specialized in manufacturing research grade antibodies, acquired Expedeon's Proteomics and Immunology Business for an undisclosed amount. The acquisition is expected to help Abcam to enhance its protein conjugation technology and to create new products for supporting research and diagnostic development. Expedeon Ltd. is a UK-based company that specializes in the development of next-generation tools for biological research, diagnostics, and drug discovery. Major players in the proteomics market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Danaher Corporation, Merck KGaA, Waters Corporation, Perkinelmer Inc., Bio-Rad Laboratories Inc., Bruker Corporation, GE Healthcare, Caprion Biosciences, Luminex Corporation, LI-COR Inc., Becton Dickinson and Company, Siemens Ltd, Genzyme Corporation, Creative Proteomics, and Promega Corporation. The regions covered in the proteomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the proteomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global proteomics market is segmented - 1) By Component: Reagents, Instruments 2) By Instrument: Protein Microarrays, Spectroscopy, X-Ray Crystallography, Chromatography, Electrophoresis, Surface Plasmon Resonance, Protein Fractionation 3) By Service and Software: Core Proteomics Services, Bioinformatics Software and Services

The cancer monoclonal antibodies market consists of sales of monoclonal antibodies used for the treatment of cancer and related services by entities (organizations, sole traders and partnerships) that produce monoclonal antibodies for cancer treatment. Monoclonal antibodies are highly specific molecules for cancer cells as they bind to the proteins on their surface and it activates an immune response. The market consists of revenue generated by cancer monoclonal antibodies companies manufacturing cancer monoclonal antibodies drugs. The main types of monoclonal antibody therapies in cancer monoclonal antibodies are bevacizumab (avastin), rituximab (rituxan), trastuzumab (herceptin), cetuximab (erbitux) and panitumumab (vectibix). Avastin is a medication that helps people with wet age-related macular degeneration (AMD). It can also be employed to treat diabetic eye problem and other retinal issues. It's administered into the eye to assist delay the loss of eyesight caused by certain disorders. The different applications include breast cancer, blood cancer, liver cancer, brain cancer, colorectal cancer, others and involves various sectors such as hospitals and clinics, research laboratories, pharmacies, others. The global cancer monoclonal antibodies market size is expected to grow from $49.81 billion in 2021 to $56.00 billion in 2022 at a compound annual growth rate (CAGR) of 12.4%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cancer MAbs market is expected to reach $86.23 billion in 2026 at a CAGR of 11.4%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer monoclonal antibodies market. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the cancer monoclonal antibodies market. The high costs involved in the development of monoclonal antibodies with advanced techniques act as a major restrain for the market due to the complex production process, expensive biological and chemical materials, and clinical trials, as well as required safety, efficacy, and quality tests. Advanced equipment is required for the large-scale production of monoclonal antibodies that encompass multiple disulfide bonds and post-translational modifications, and this equipment is expensive. Clinical efficacy is usually achieved by injecting large amounts of monoclonal antibodies into the system, which means that large quantities are required to be produced for each treatment, thus increasing the cost. According to The American Journal of Managed Care, the annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states. Thus, the high development costs in using these advanced techniques will restrain market growth. Companies in the cancer monoclonal antibodies market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as academic and research institutions in this market by way of partnerships and in- or out-licensing deals, this trend has been increasing over recent years. For instance, in September 2020, AbbVie and I-Mab entered into a strategic partnership for the development and commercialization of lemzoparlimab (also known as TJC4), which is a monoclonal antibody drug used to treat multiple cancers. In September 2019, IRBM announced the signing of a service and development agreement with The University of Texas MD Anderson Cancer Center. The agreement will focus on the development of therapeutic monoclonal antibodies for cancer. In March 2020, Gilead Sciences, a US-based biopharmaceutical company, announced its decision to acquire Forty Seven for $4.9 billion. This acquisition is expected to strengthen Gilead’s immuno-oncology R&D portfolio with the addition of Forty Seven’s investigational lead product candidate, magrolimab. Magrolimab is a monoclonal antibody in clinical development for the treatment of several cancers. Forty Seven Inc. is a clinical-stage immuno-oncology company that develops therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed from Stanford University. Major players in the cancer monoclonal antibodies market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co., and Spectrum Pharmaceuticals. The regions covered in the cancer monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cancer MAbs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global cancer monoclonal antibodies market is segmented - 1) By Monoclonal Antibody Therapies: Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Others 2) By Application: Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Others 3) By End-User: Hospitals and Clinics, Research Laboratories, Pharmacies, Others

The conjugated monoclonal antibodies market consists of the sales of conjugated monoclonal antibodies. Conjugated monoclonal antibodies are monoclonal antibodies (MAbs) associated with a chemotherapy drug or a radioactive particle. These are used in the treatment of cancer as they deliver the toxic substance directly to the tumor cells by reducing damage to normal cells in other parts of the body. The main types of drugs in conjugated monoclonal antibodies are adcetris and kadcyla. Adcetris is a brand-name pharmaceutical drug intended to cure adults with certain types of lymphoma. Lymphoma is a cancer which attacks the lymphatic system and lymphocytes, that are white blood cells. The different technologies include cleavable linker, non-cleavable linker and is used in blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumour, others. The global conjugated monoclonal antibodies market size is expected to grow from $8.89 billion in 2021 to $9.64 billion in 2022 at a compound annual growth rate (CAGR) of 8.5%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The conjugated MAbs market is expected to reach $12.09 billion in 2026 at a CAGR of 5.8%. The increasing popularity and therapeutic potential of conjugated monoclonal antibodies especially antibody-drug conjugate is expected to drive the conjugated monoclonal antibodies market over the forecast period. Antibody-drug conjugates (ADCs), are class of therapeutics consisting of monoclonal antibodies (MAbs) clubbed with highly potent cytotoxic drugs through a linker to kill the antigen-expressing tumor cells, predominantly used in the treatment of cancer. The U.S. Food and Drug Administration approved only five antibody-drug conjugates drugs till 2018 and in 2019, it has approved three antibody-drug conjugates drugs indicating that the increased number of approvals is directly proportional to the use of conjugated monoclonal antibodies mainly in the field of cancer which in turn aids in the growth of the market. The high cost of conjugated monoclonal antibodies is anticipated to limit the growth of the conjugated monoclonal antibodies market. For instance, the cost of the first FDA approved radioimmunotherapy drug Yttrium 90 Ibritumomab Tiuxetan therapeutic (Zevalin) is priced at around $55,000. Moreover, Padcev, an antibody-drug conjugate from Seattle Genetics and Astellas which was approved in December 2019 cost between $110,000 to $120,000 for a course of treatment. The high cost of the therapy makes it unaffordable for the patients and healthcare systems of underdeveloped countries which hinders the growth of the conjugated monoclonal antibodies market. Companies operating in the conjugated monoclonal antibodies market are focusing on strategic collaborations and partnerships for developing new conjugated monoclonal antibodies shaping the market. For instance, in October 2019 NovoCodex, a subsidiary of Zhejiang Medicine Co Ltd collaborated for the second time with Ambrx Inc, a USA-based company engaged in developing protein therapeutics to develop and commercialize Ambrx's internally developed site-specific antibody-drug conjugate, ARX305 used for the treatment of CD70 positive cancers. Following the trend, in June 2020, Monopar Therapeutics, a USA-based biopharmaceutical company, and NorthStar Medical Radioisotopes entered in collaboration to couple Monopar’s MNPR-101 a humanized urokinase plasminogen activator receptor (uPAR) targeted monoclonal antibody in pre-IND stage to a therapeutic radioisotope of NorthStar to create a highly selective agent, which has the potential to kill aberrantly activated cytokine-producing immune cells. In July 2020, AstraZeneca, a UK-based drugmaker has entered into a partnership with Daiichi Sankyo for an amount of $6 billion. This deal is for the global development and commercialization of DS-1062, a TROP2-targeted antibody-drug conjugate (ADC) which is a type of drug that works by using a monoclonal antibody to deliver an attached pharmaceutical payload directly to tumor cells. Daiichi Sankyo is a Japanese based pharmaceutical company engaged in the development of antibody-drug conjugates. Major players in the conjugated monoclonal antibodies market are Pfizer Inc., F. Hoffmann-LA, Bristol -Myers Squibb, Merck & Co. Inc., Immunomedics Inc., Takeda Pharmaceuticals Industries Ltd., Daiichi Sankyo Company Limited, Actinium Pharmaceutical, Nordic Nanovector Inc., and Spectrum Pharmaceuticals Inc. North America was the largest region in the conjugated monoclonal antibodies market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the conjugated MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the conjugated monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global conjugated monoclonal antibodies market is segmented - 1) By Drug: Adcetris, Kadcyla 2) By Technology: Cleavable Linker, Non-Cleavable Linker 3) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumour, Others

The monoclonal antibodies (MAbs) market consists of sales of monoclonal antibodies and related services. Monoclonal antibodies are used to enhance and suppress the immune response in various medical conditions and to treat various diseases such as cancer, cardiovascular and cerebrovascular diseases. This industry includes establishments that produce anti-cancer monoclonal antibodies to prevent metastasis by reducing cell proliferation, immunological monoclonal anti-bodies, neuropharmacological monoclonal anti-bodies, anti-infective monoclonal antibodies, and other MAbs for human beings and animals. The main types of sources in monoclonal antibodies (MAbs) are murine, chimeric, humanized and human. A murine antibody has two types of chains, one of which is from a mouse and the other from a human. The pre-stem -o- in a murine antibody's INN is used to identify it. It is used in anti-cancer, immunological, anti-infective MAbs, neuropharmacological, cardiovascular and cerebrovascular, others and implemented in various sectors such as hospitals, private clinics, research institute. The global monoclonal antibodies (MAbs) market size is expected to grow from $168.70 billion in 2021 to $188.18 billion in 2022 at a compound annual growth rate (CAGR) of 11.5%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The MAbs market is expected to reach $292.22 billion in 2026 at a CAGR of 11.6%. The Increasing prevalence of cost-efficient biosimilar monoclonal antibodies are driving the monoclonal antibodies market growth. The biosimilar aim is to curb the increasing healthcare cost and handle economic pressure from the patient pod and governments to reduce the cost of medication and increase access to treatment. Biosimilar is the pharmaceuticals that are developed to have similar properties to a biologic drug that has already been approved. A biosimilar monoclonal antibody costs 20%-25% lesser than the originator biologic drug. The number of clinical trials for a biosimilar is comparatively lesser than that of the original biologic drug and this proves to be the reason for the low cost of a biosimilar drug. In India, a new biosimilar policy called the ‘Guidelines on Similar Biologics’ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilar drugs industry. Alternative treatment methods and natural remedies are increasingly becoming popular globally and this is expected to have a negative impact on the revenues of the monoclonal antibody drugs market. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, the revenue of US retail sales of homeopathic and herbal remedies was around $7.5 billion. These less expensive alternatives increase competitiveness for the biologics market putting downward pressure and limiting the demand for monoclonal antibody drugs. The monoclonal antibodies market has been witnessing multiple strategic initiatives in recent years. Top companies in the market are strategically acquiring start-ups and mid-sized companies to broaden products and services. Strategic collaborations or acquisitions and partnership agreements help vendors expand their existing product portfolio and geographical reach. For instance, In February 2019, AbCellera and Novartis enter into a multi-target partnership to create an antibody-drug discovery platform and technology for treating clinically-relevant and neurodegenerative diseases. Furthermore, AbCellera collaborated with GlaxoSmithKline (GSK), a pharmaceutical company, for the discovery of monoclonal antibodies against an undisclosed membrane protein target. Merck completed the acquisition of Sigma-Aldrich Corp., a leading life science company. Post this acquisition, Merck has more than 50,000 employees, 72 manufacturing sites, and a presence in 67 countries worldwide. Companies in the industry are increasingly realigning their portfolios and pursue profitable inorganic growth opportunities. Additionally, M&A interest is also being fueled by stronger corporate balance sheets, liquid debt markets, and continued favorable interest rates globally. The Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human Services, in the USA regulating the monoclonal antibodies and pharmaceutical drugs market. Increasing product launches and regulatory support for the treatment of rare diseases by USFDA is expected to support the monoclonal antibody therapeutics market growth. For instance, the U.S. FDA granted accelerated approval to avelumab (BAVENCIO, EMD Serono, Inc.), a human monoclonal antibody, for the treatment of a rare disease, metastatic Merkel cell carcinoma (MCC). Similarly, the U.S FDA granted accelerated approval to immunotherapy product- TECENTRIQ (atezolizumab), a humanized, engineered monoclonal antibody, for the treatment of people with locally-advanced or metastatic urothelial carcinoma (mUC). Major players in the monoclonal antibodies (MAbs) market are Johnson & Johnson, Merck, AbbVie, Amgen, GlaxoSmithKline plc., Norvatis AG, Pfizer Inc, Thermofischer Scientific, Elililly and Company and Bristol-Myers Squibb. The regions covered in the monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the MAbs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global monoclonal antibodies (MAbs) market is segmented - 1) By Source: Murine, Chimeric, Humanized, Human 2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular and Cerebrovascular, Others 3) By End-User: Hospitals, Private Clinics, Research Institutes

The hematology diagnostics devices and equipment market consist of sales of hematology diagnostics devices and related services. Hematology diagnostics instruments are used to diagnose diseases related to blood, vascular systems, bone marrow, autoimmune disorders, and hemostasis. These devices include automated cell counters, red cell indices devices, micro sedimentation centrifuges, blood volume measuring devices, occult blood tests, platelet aggregometer, erythrocyte sedimentation rate tests, red blood cell enzyme assay kits, glutathione reductase assays, and hematology reagents. The main products of the hematology diagnostics devices and equipment are instruments and consumables. Hematology diagnostics instruments are used to diagnose diseases related to blood, vascular systems, bone marrow, autoimmune disorders, and hemostasis. The hematology diagnostics consumables involved are reagents, stains, and others and hematology diagnostics instruments involved are analyzers, flow cytometers, and others. These are used in various applications including drug testing, autoimmune disease, cancer, diabetes mellitus, infectious disease, and other applications. The end-users are hospitals, specialized diagnostic centers, and specialized research institutes. The global hematology diagnostic devices and equipment market size is expected to grow from $1.64 billion in 2021 to $1.91 billion in 2022 at a compound annual growth rate (CAGR) of 16.4%. The global hematology diagnostic devices market size is expected to grow to $3.28 billion in 2026 at a CAGR of 14.5%. Hematology diagnostic devices are driven by the increase in the prevalence of blood disorders. Hematology diagnostic devices are widely used to identify the type of blood disorder. A blood disorder is a condition which is impacting the count of the blood cells like red blood cells, white blood cells, platelets, etc. Blood disorders affect millions of people each year across the world irrespective of age, race, and sex. E.g. As per the World Health Organization, Hemoglobin disorder is affecting 75% of the total births globally and the prevalence of Anemia is 12.7% in men. Product recall is one of the major problems that companies are facing. Product recalls are the process of returning faulty devices which can be due to errors in the manufacturing of the device. Because of the faulty devices tests conducted in the diagnostic centers may get affected. For example, Becton Dickinson (BD) and Company recalled Vacutainer EDTA Blood Collection Tubes because they are affecting the test due to the chemical interference of test tubes with the blood samples. This recall was classified as Class I recall, the most serious type of recall, by the Food and Drug Administration (FDA). Such product recalls can negatively affect market growth. Companies in hematology diagnostic devices are increasingly investing in automation technology. Automation technology advancements are driving the demand for hematology analyzers and this automation will reduce the errors caused due to the manual practices in the diagnostic centers. Example top companies like Sysmex acquired CLIA waiver for a new automated hematology analyzer and by selling this product, Sysmex makes it possible for clinical facilities to perform hematology testing without any manual errors. CLIA regulations establish quality standards for laboratory testing performed on specimens from humans, such as blood, body fluid, and tissue, for diagnosis, prevention, or treatment of disease, or assessment of health. The hematology diagnostic devices market has a potential market to grow rapidly but stringent regulatory policies are restricting their growth. The FDA currently regulates class I, class II, and class III hematology devices. This means that class I hemostasis devices are regulated to use these devices are exempt from the premarket notification requirements and they only be used for the general controls. Regulations for class II devices are exempt from the premarket notification requirements and they can be used for special controls. Class III is the most stringent category as it requires premarket approval (PMA). Major players in the hematology diagnostics devices and equipment market are Abbott Diagnostics, Beckman Coulter, Bio-Rad Laboratories, Drucker Diagnostics, Horiba Ltd, Instrumentation Laboratory Inc, Siemens Healthcare, Shenzhen Mindray Bio-Medical Electronics Co Ltd, F. Hoffmann-La Roche AG, and Thermo Fisher Scientific Inc. North America was the largest region in the hematology diagnostics devices and equipment market in 2021. Asia Pacific was the second-largest region in the global hematology diagnostic equipment market. The regions covered in the global hematology diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the hematology diagnostic devices market report are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The global hematology diagnostic devices and equipment market is segmented - 1) By Product: Instruments, Consumables 2) By End-User: Hospitals, Specialized Diagnostic Centers, Specialized Research Institutes 3) By Instrument: Analyzers, Flow Cytometers, Others 4) By Consumable: Reagents, Stains, Others 5) By Application: Drug Testing, Auto Immune Disease, Cancer, Diabetes Mellitus, Infectious Disease, Others